EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access

Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis

Lisa P van der Rijst, Esmé Kamphuis, Marie L A Schuttelaar, Rimoon Hurmuz, Marieke M B Seyger, Anouk G M Caron, Nicolaas P A Zuithoff, N Tan Nguyen, Marijke Kamsteeg, Marjolein S de Bruin-Weller, Suzanne G M A Pasmans, Maritza A Middelkamp-Hup und 1 weitere

JAMA Dermatology · 2025

DOI: 10.1001/jamadermatol.2024.3717 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Dermatology, 2025. Verfasst von Lisa P van der Rijst und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlan…. Hauptthemen laut MEDLINE: Methotrexate, Dermatitis, Atopic, Cyclosporine, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Dupilumab, methotrexate (MTX), and cyclosporine A (CsA) are valuable treatment options for pediatric patients with refractory moderate to severe atopic dermatitis (AD). Yet, comparative data on these treatments in pediatric patients are scarce.

Objective

To evaluate drug survival of dupilumab, MTX, and CsA, and identify associated predictors in a multicenter daily practice cohort study of pediatric patients with AD. Design, Setting, and Participants This multicenter daily practice cohort study included patients with AD aged 2 to 17 years treated with dupilumab, MTX, and/or CsA in 5 tertiary centers in the Netherlands between 2013 and 2023. Data were extracted from the prospective BioDay and TREAT Netherlands registries and electronic medical records. Exposures Dupilumab, MTX, CsA. Main Outcomes and Measures Drug survival was analyzed using Cox proportional hazard regression models. Univariable and multivariable Cox regression analyses were conducted to identify variables associated with drug discontinuation.

Results

A total of 502 treatment episodes in 362 unique patients were included, comprising 192 dupilumab episodes, 94 MTX episodes, and 216 CsA episodes. Overall, the mean (SD) age at treatment initiation was 12.9 (3.8) years, and 272 treatment episodes (54.2%) in female patients. The 1-year, 2-year, and 3-year overall drug survival rates, respectively, were 84.1%, 72.3%, and 62.0% for dupilumab; 60.7%, 39.3%, and 25.3% for MTX; and 43.9%, 21.5%, and 10.4% for CsA. Ineffectiveness was the most frequent reason for drug discontinuation, accounting for 178 episodes (35.5%), mostly in patients treated with CsA, followed by adverse effects in 94 patients (18.7%). Treatment with MTX and treatment with CsA were independently associated with a higher risk for drug discontinuation due to ineffectiveness (hazard ratio [HR], 4.45 [95% CI, 2.38-8.34] and HR, 10.88 [95% CI, 6.23-19.02], respectively) and adverse effects (HR, 4.39 [95% CI, 2.05-9.39] and HR, 3.83 [95% CI, 1.85-7.92], respectively) compared to treatment with dupilumab. Patients aged 12 to 17 years starting systemic treatment were independently associated with a higher risk for drug discontinuation due to ineffectiveness (HR, 1.55 [95% CI, 1.10-2.20]) and adverse effects (HR, 2.39 [95% CI, 1.33-4.30]). Conclusions and Relevance This multicenter daily practice cohort study demonstrated a superior 1-year, 2-year, and 3-year overall drug survival for dupilumab, followed by MTX, with the lowest rates observed for CsA in pediatric patients with AD. This study also identified characteristics associated with discontinuation. These results provide insight into drug survival resulting from the effectiveness, safety, and tolerability of these systemic treatments in pediatric patients with AD and contribute to the optimization of patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateDermatitis, AtopicCyclosporineAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansFemaleChildMaleChild, PreschoolAdolescentNetherlandsTreatment OutcomeCohort StudiesProspective StudiesProportional Hazards ModelsImmunosuppressive AgentsSeverity of Illness Index

Substanzen

MethotrexatedupilumabCyclosporineAntibodies, Monoclonal, HumanizedDermatologic AgentsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Dermatology and Allergology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands.
  • Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Dermatology, Radboud Medical Center, Nijmegen, the Netherlands.
  • Department of Dermatology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.

Zitieren

APA

van der Rijst, L. P., Kamphuis, E., Schuttelaar, M. L. A., Hurmuz, R., Seyger, M. M. B., Caron, A. G. M., Zuithoff, N. P. A., Nguyen, N. T., Kamsteeg, M., de Bruin-Weller, M. S., Pasmans, S. G. M. A., Middelkamp-Hup, M. A., & de Graaf, M. (2025). Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.3717

Vancouver

van der Rijst LP, Kamphuis E, Schuttelaar MLA, Hurmuz R, Seyger MMB, Caron AGM, et al. Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2024.3717

BibTeX
@article{vanderRijst2025,
  author = {van der Rijst, Lisa P and Kamphuis, Esmé and Schuttelaar, Marie L A and Hurmuz, Rimoon and Seyger, Marieke M B and Caron, Anouk G M and Zuithoff, Nicolaas P A and Nguyen, N Tan and Kamsteeg, Marijke and de Bruin-Weller, Marjolein S and Pasmans, Suzanne G M A and Middelkamp-Hup, Maritza A and de Graaf, Marlies},
  title = {Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis},
  journal = {JAMA Dermatology},
  year = {2025},
  doi = {10.1001/jamadermatol.2024.3717}
}
Kostenlos starten →